Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - Concert Pharmaceuticals, Inc. (Private) |
|
|
“The vision behind Concert is to take a different tack at drug discovery that would enable the creation of new chemical entities (NCEs), first-and best-in-class new medicines, in a way that substantially reduces the risks associated with current drug development approaches and increases the likelihood of their successful commercial development.” - Roger Tung, Ph.D. (Interview published February 19, 2009) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Sept. 14, 2009 07:30 ET
Concert Pharmaceuticals Presents Clinical Results Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified CompoundPhase I Results Presented at American College of Clinical Pharmacology
SAN ANTONIO--(BUSINESS
WIRE)--
Concert Pharmaceuticals, Inc. announced
today the presentation of Phase 1 data on CTP-347, a
deuterium-modified analog of paroxetine for the
treatment of
hot flashes. Concert presented the results
during a
poster
session at the American College of Clinical
Pharmacology’s 38th Annual Meeting. This
presentation highlighted that subjects treated with
CTP-347 substantially retained cytochrome P450 2D6
(CYP2D6)
enzyme
activity. This enzyme is necessary for the
metabolism of many common drugs, but is irreversibly
inactivated by a metabolite of paroxetine, causing
significant drug-drug interactions. Concert believes
these findings represent the first reported clinical
data demonstrating that deuterium substitution can
alter a drug’s metabolism to reduce the potential
for drug-drug interactions in humans.
“This proof-of-concept study, combined with our preclinical findings, demonstrates how we can apply deuterium chemistry to a proven drug to suppress formation of an undesirable metabolite, while retaining the drug’s beneficial pharmacologic activity,” said Roger Tung, Ph.D., President and Chief Executive Officer. “These are exciting results and provide one example of how our deuterium chemistry platform can leverage proven drugs to create highly differentiated yet risk-reduced new medicines.” The Phase 1 clinical trial was a randomized, single-blind, placebo-controlled, ascending single- and multiple-dose study in 94 healthy volunteers. The primary objective of the study was to evaluate the safety, tolerability and pharmacokinetics of CTP-347. In this trial, CTP-347 was well-tolerated at all doses evaluated and there were no clinically significant adverse events reported. The most common adverse events were typical of selective serotonin reuptake inhibitors (SSRIs) including headache, nausea and dizziness. In vitro studies have previously shown that CTP-347, unlike paroxetine, does not exhibit mechanism-based inactivation of CYP2D6 in human liver microsomes. The pharmacokinetics of CTP-347 were consistent with those observed in preclinical studies. CTP-347 is a new chemical entity developed from Concert’s deuterium chemistry platform by replacing key hydrogen atoms of paroxetine with deuterium as a non-hormonal treatment for vasomotor symptoms (VMS) or hot flashes. Paroxetine has been shown to be an effective treatment for VMS. However, it is a potent and irreversible inactivator of CYP2D6 (cytochrome P450 2D6), a key liver enzyme responsible for the metabolism of many commonly-prescribed drugs. Currently, there is no FDA-approved non-hormonal treatment for VMS, a serious and sometimes long-term condition associated with a range of undesirable effects including depression, insomnia and lost productivity. Hormone replacement therapy can effectively treat VMS. However, patients who currently or previously have been treated for cancers of the breast or ovary, or who have a familial history of these cancers, are often advised to avoid hormonal treatment. A non-hormonal therapy may also be preferred by women who experience VMS following menopause in whom hormone therapy is contraindicated or who have concerns about long-term health risks posed by hormone replacement therapy. About Deuterium Deuterium is a safe, non-radioactive relative of hydrogen that can be isolated from sea water and has been used extensively in human metabolic and clinical studies. Since deuterium resembles hydrogen, deuterium-containing compounds are expected to preserve the pharmacological activity of their hydrogen analogs. An important difference is that deuterium is heavier than hydrogen and therefore forms a stronger chemical bond to a carbon atom of a drug. The stronger chemical bond obtained by selective deuterium modification in select instances may substantially improve the drug’s metabolic properties, potentially resulting in better safety, tolerability and/or efficacy. About Concert Concert Pharmaceuticals is a clinical stage biotechnology company focused on the application of deuterium chemistry to create novel small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. Its lead development candidate is the HIV protease inhibitor CTP-518. In 2009, Concert entered into a potential $1 billion collaboration with GlaxoSmithKline to develop certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com. CoNCERT and CoNCERT Pharmaceuticals are trademarks of Concert Pharmaceuticals, Inc. Contacts
Investors:
Concert Pharmaceuticals, Inc. Justine E. Koenigsberg, 781-674-5284 or Media: Yates PR Kathryn Morris, 845-635-9828
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.